Press Releases :: Aurinia Pharmaceuticals Inc. (AUPH)

March 5, 2020 • 4:02 pm EST

Aurinia Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights

March 3, 2020 • 6:30 am EST

Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results on March 5, 2020

February 25, 2020 • 6:30 am EST

Aurinia Appoints Max Colao as Chief Commercial Officer and Expands U.S. Commercial Leadership Team

February 21, 2020 • 4:05 pm EST

Aurinia Pharmaceuticals to Present at the 9th Annual SVB Leerink Global Healthcare Conference

December 12, 2019 • 9:26 am EST

Aurinia Closes US$191.7 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares

December 9, 2019 • 9:00 pm EST

Aurinia Prices US$166.7 Million Public Offering of Common Shares

December 9, 2019 • 6:01 am EST

Aurinia Announces Public Offering of Common Shares

December 4, 2019 • 4:05 pm EST

Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis

December 3, 2019 • 6:30 am EST

Aurinia to Present Preclinical Voclosporin Data at 2020 Keystone Symposia Conference

November 14, 2019 • 4:02 pm EST

Aurinia Reports Third Quarter 2019 Financial Results and Recent Operational Highlights

Select a page:

rss_feed News RSS

©2025 Aurinia Pharmaceuticals Inc. All Rights Reserved. US-LUP-2300105 08/23